EBS

#3046
Emergent Biosolutions, Inc.
8.0600 USD
+0.37%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
8.0301
8.0750
Faixa anual
7.7400
11.4600
Mudança diária
+0.37%
Mudança mensal
+0.25%
Mudança em 6 meses
-24.81%
Mudança anual
-24.81%
Fechamento anterior
8.0300
Abrir
8.0575
Mínimo
8.0301
High
8.0750
Volume
159
Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
  • Market Capitalization 417.2731 M
  • Employee 900
  • Founded 1998
  • CEO Robert G. Kramer Sr.Joseph C. Papa
  • Website www.emergentbiosolutions.com
  • Headquarter Delaware, United States
  • FIGI BBG000GW06J7
  • Industry Fabricantes de medicamentos - especializados e genéricos
Receita total
Lucro líquido
Lucro básico por ação
Dívida total
Fluxo de caixa livre
Caixa e equivalentes de caixa
Índice preço/lucro
13.29
Índice preço/fluxo de caixa
0.94

Emergent BioSolutions Inc

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.

Notícias